MK-8776, a Novel Chk1 Kinase Inhibitor, Radiosensitizes P53-Defective Human Tumor Cells

Oncotarget - United States
doi 10.18632/oncotarget.12311
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

The Chk1 Inhibitor MK-8776 Increases the Radiosensitivity of Human Triple-Negative Breast Cancer by Inhibiting Autophagy

Acta Pharmacologica Sinica
MedicinePharmacology
2017English

The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Small-Molecule Inhibition of Wee1 Kinase by MK-1775 Selectively Sensitizes P53-Deficient Tumor Cells to DNA-damaging Agents

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Erratum: Corrigendum: A Ruthenium Polypyridyl Intercalator Stalls DNA Replication Forks, Radiosensitizes Human Cancer Cells and Is Enhanced by Chk1 Inhibition

Scientific Reports
Multidisciplinary
2016English

CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

A Designed Inhibitor of P53 Aggregation Rescues P53 Tumor Suppression in Ovarian Carcinomas

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Novel CHK1 Inhibitor MU380 Exhibits Significant Single-Agent Activity in TP53-mutated Chronic Lymphocytic Leukemia Cells

Haematologica
Hematology
2019English

Chk1 Inhibition Activates P53 Through P38 MAPK in Tetraploid Cancer Cells

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2008English

MLN8054, an Inhibitor of Aurora a Kinase, Induces Senescence in Human Tumor Cells Both in Vitro and in Vivo

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy